Market News & Trends
12/12/2012
TNF Inhibitors Lay Groundwork for Next-Generation of Disease-Modifying Anti-Rheumatic Drugs The challenges inherent in the pharmacological management of rheumatic diseases have stoked huge demand for…
Isis Pharmaceuticals Announces $31-Million Strategic Cancer Alliance
Isis Pharmaceuticals, Inc. and AstraZeneca recently announced a strategic alliance for the discovery and development of novel-generation antisense therapeutics against five cancer targets, which includes…
Moderna Therapeutics Secures $40 Million for New Way of Making Therapeutic Proteins
Moderna Therapeutics recently announced it has closed more than $40 million in financing to date, led by Flagship Ventures and private investors, which will be…
New Genomic Biomarker Services to Improve Drug Development Pipelines
EMD Millipore's Discovery and Development Solutions business, part of the Life Science division of Merck KGaA of Darmstadt, Germany, recently announced it will now offer…
Pearl Therapeutics Issued US Patent on Co-Suspension Formulation Technology
Pearl Therapeutics Inc. recently announced that the US Patent and Trademark Office has issued a patent on its novel co-suspension formulation technology for inhaled combinations.…
Teva Enters $376-Million Deal for Xenon's Pain Drug
Teva Pharmaceutical Industries Ltd and Xenon Pharmaceuticals Inc. recently announced they have entered into a collaborative development and exclusive worldwide license for XEN402, which is…
TNF Inhibitors Lay Groundwork for Next-Generation of Disease-Modifying Anti-Rheumatic Drugs
The challenges inherent in the pharmacological management of rheumatic diseases have stoked huge demand for drug classes with excellent safety and efficacy profiles. While tumor…
Tekmira Acquires Worldwide License to Novel RNAi Technology
Tekmira Pharmaceuticals Corporation recently announced it has obtained a worldwide, non-exclusive license to a novel RNAi payload technology called Unlocked Nucleobase Analog (UNA) from Marina…
12/5/2012
Curis Announces Several Major Announcements Curis, Inc. recently announced it has licensed from Genentech, a member of the Roche Group, exclusive worldwide rights for the…
Curis Announces Several Major Announcements
Curis, Inc. recently announced it has licensed from Genentech, a member of the Roche Group, exclusive worldwide rights for the development and commercialization of GDC-0917,…
Governor Jindal, AgraTech International Announce New Chitosan Facility
Governor Bobby Jindal and AgraTech International Inc. Chairman Richard DeMarco recently announced the company will renovate a former Opelousas bottling facility, creating 50 new direct…
Hovione & Solvias Announce Drug Solubility Collaboration
Hovione and Solvias recently announced the establishment of a collaboration focused on the development and GMP supply of pharmaceutical co-crystals. This strengthens Hovione's expertise and…
New Technology for Producing Thermostable Vaccines
Bend Research Inc., PATH, and Fraunhofer USA Center for Molecular Biotechnology (FhCMB) recently announced the development of a new technology for the production of thermostable…
Selecta Biosciences & Sanofi Sign Global Collaboration
Selecta Biosciences, Inc. recently announced it has entered into a strategic global collaboration with Sanofi to discover highly targeted, antigen-specific immunotherapies for life-threatening allergies. Under…
11/28/2012
CoreRx & ViroPro Announce Agreement CoreRx, Inc. and Viropro, Inc. recently announced the two companies have entered into a Reciprocal Referral Agreement. The Agreement will…
BASF Plans to Acquire Pronova BioPharma
BASF recently announced it plans to acquire Pronova BioPharma ASA, Lysaker, Norway, a pioneer in the field of research, development, and manufacturing of omega-3 fatty…
CoreRx & ViroPro Announce Agreement
CoreRx, Inc. and Viropro, Inc. recently announced the two companies have entered into a Reciprocal Referral Agreement. The Agreement will benefit both companies' existing and…
Genzyme Corporation Announces Drug Approval
Genzyme, a Sanofi company, recently announced that the Australian Therapeutic Goods Administration (TGA) has approved AUBAGIO (teriflunomide) 14 mg as a new once-daily, oral treatment…
MethylGene Closes Substantial Private Placement
MethylGene Inc. recently announced it has completed its previously announced private placement of 179,690,970 units at a subscription price per unit of Cdn.$0.145 (the Subscription…
Teva to Focus on Smaller M&A
Teva Pharmaceutical Industries Ltd. is shifting away from the multi-billion dollar acquisitions that have defined its growth for the past decade, indicating acquisitions don't have…
